跳至主要内容
临床试验/NCT07585097
NCT07585097招募中不适用

Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)

Ipsen14 个研究点 分布在 2 个国家目标入组 30 人开始时间: 2026年7月10日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Ipsen
入组人数
30
试验地点
14

研究概览

简要总结

This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.

The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
6 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with ALGS.
  • On (or starting) active odevixibat treatment.
  • Aged 6 months or older at the time of consent.

排除标准

  • Currently participating in a clinical trial with odevixibat.
  • Currently participating in any interventional clinical trial for ALGS.
  • Have any contraindication to odevixibat as per the locally approved label.

研究者

发起方
Ipsen
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验